Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0458 EUR | +0.88% | -6.15% | +48.70% |
06-17 | Percheron Therapeutics Appoints CFO | MT |
06-03 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+48.70% | 51.13M | - | ||
+15.20% | 121B | B+ | ||
+19.67% | 113B | B+ | ||
+18.95% | 26.02B | B | ||
-23.86% | 19.39B | B+ | ||
-19.03% | 15.91B | A- | ||
-20.90% | 15.09B | B | ||
-46.14% | 15.06B | A- | ||
+63.85% | 14.93B | C+ | ||
+4.49% | 13.85B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PER Stock
- AWY0 Stock
- Ratings Percheron Therapeutics Limited